1. What happened
Under a seven-figure multiyear agreement, OneMedNet will deliver de-identified multimodal longitudinal clinical RWD through its iRWD platform to an undisclosed commercially scaled AI-enabled precision-medicine company. The customer intends to train clinical and diagnostic AI models and create a licensable derivative dataset combining its molecular data with OneMedNet imaging and longitudinal clinical journeys. OneMedNet retains source-data rights and receives incremental annual sublicensing revenue when the derivative solution is licensed to end customers.
2. Buyer / seller
Undisclosed commercially scaled AI-enabled precision-medicine company is the AI buyer or model-development side. OneMedNet owns or contributes the proprietary corpus.
3. Economics
Seven-figure multiyear agreement, plus incremental annual sublicensing revenue to OneMedNet for each downstream end-customer license; exact contract value, currency, payment form, annual schedule and per-license revenue share are not disclosed in the reviewed issuer announcement. Economics scope: The disclosed seven-figure amount applies to the multiyear data license. OneMedNet separately states that it receives recurring sublicensing revenue on each downstream license of the derivative product and that the agreement includes an option to expand data volume and contract value; exact values are not disclosed.. Strategic Signal has not estimated undisclosed consideration.
4. Proprietary data
De-identified, multimodal, longitudinal clinical real-world data sourced directly through OneMedNet's network of more than 2,300 healthcare partner sites, including medical imaging and longitudinal clinical journeys, licensed for AI model training and incorporation into a commercial derivative dataset. Historical depth: OneMedNet describes longitudinal clinical journeys and a network encompassing more than 90 million patient journeys and 270 million studies, but the specific licensed subset's years of history and patient count are not disclosed.. Refreshability: The arrangement is multiyear, uses a live network of more than 2,300 healthcare partner sites, includes recurring downstream licensing and provides an option to expand data volume, supporting a renewable rather than one-time corpus..
5. Rights and restrictions
Data are delivered under a multiyear commercial license through OneMedNet's iRWD platform; OneMedNet retains source-data rights and derivative end customers may not relicense or resell the underlying OneMedNet data. Ownership: Prohibited for the source data: OneMedNet expressly states that it retains source-data rights.. Training: Permitted and explicit: the customer intends to use OneMedNet data to train AI-enabled clinical and diagnostic models.. Post-training: not disclosed.
6. Why the data matters for AI
Training clinical and diagnostic AI models and constructing a commercial derivative dataset that combines OneMedNet imaging and longitudinal clinical journeys with the customer's molecular datasets. The licensed corpus links imaging and longitudinal clinical records across patient journeys and is intended for clinical and diagnostic model development. The reviewed disclosure does not establish accessible context-intervention-outcome linkage sufficient to infer canonical Human Response H2 or H3.
7. Asset Score — 94/100
Strategic Signal analysis. OneMedNet's direct-from-source multimodal clinical corpus is large, longitudinal, renewable, real-world and explicitly useful for AI training, with strong scarcity and derivative-product utility; exact licensed-subset depth and intervention-to-outcome linkage remain undisclosed. Score coverage: 100%.
| Factor | Weight | Rating / 5 | Points |
|---|---|---|---|
| Uniqueness / scarcity | 12 | 4.5 | 10.8 |
| Historical depth | 8 | 4 | 6.4 |
| Decision → outcome richness | 13 | 4 | 10.4 |
| Decision Value Density | 13 | 5 | 13.0 |
| Real-world grounding | 10 | 5 | 10.0 |
| Domain economic value | 9 | 5 | 9.0 |
| Refreshability | 8 | 5 | 8.0 |
| Proprietary advantage | 9 | 5 | 9.0 |
| Model-learning usefulness | 10 | 5 | 10.0 |
| Non-replicability | 4 | 4.5 | 3.6 |
| Rights usability | 4 | 4.5 | 3.6 |
8. Transaction Signal Score — 78/100
Strategic Signal analysis. The transaction discloses a seven-figure multiyear data license, explicit model-training use, cleanly separable data consideration, derivative commercialization and recurring sublicensing economics. The exact price, counterparty identity, competitive process and independent model-uplift evidence remain undisclosed. Score coverage: 85%.
| Factor | Weight | Rating / 5 | Points |
|---|---|---|---|
| Disclosed economics | 16 | 3 | 9.6 |
| Clean price discovery | 16 | 2 | 6.4 |
| Separability of data consideration | 15 | 5 | 15.0 |
| Explicit training / model-improvement use | 14 | 5 | 14.0 |
| Clarity of rights purchased | 12 | 4.5 | 10.8 |
| Competing bids | 10 | Unknown | — |
| Strategic buyer quality | 6 | 3.5 | 4.2 |
| Repeatability / precedent value | 6 | 5 | 6.0 |
| Independent model-uplift evidence | 5 | Unknown | — |
9. M&A / valuation implications
The transaction provides observable evidence that proprietary healthcare data can support a layered monetization model: multiyear training-license economics plus participation in downstream derivative-data revenue while the source owner retains the underlying data rights.
10. Evidence boundary
The issuer release establishes a seven-figure multiyear license, explicit AI-model training, derivative-dataset commercialization, recurring downstream sublicensing revenue, retained source-data rights, de-identification, more than 2,300 healthcare partner sites, and an option to expand volume and value. The counterparty name, exact contract value, annual payment schedule, sublicensing rate, licensed subset size, historical years, exclusivity, retention, post-training and evaluation rights, geographic processing terms, patient consent details, model ownership and independent model-uplift evidence are not disclosed. Longitudinal patient journeys do not by themselves establish Human Response H2/H3 linkage. Currency correction: the reviewed issuer announcement uses 'seven figure' without explicitly identifying a currency or settlement form. The earlier USD field is withdrawn in this successor record; no numeric range, cash realization or currency conversion is inferred.